![]() |
市場調査レポート
商品コード
1546284
心電計(ECG)の世界市場の評価:タイプ別、技術別、リードタイプ別、エンドユーザー別、地域別、機会、予測(2017年~2031年)Electrocardiograph (ECG) Market Assessment, By Type, By Technology, By Lead Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
||||||
カスタマイズ可能
|
心電計(ECG)の世界市場の評価:タイプ別、技術別、リードタイプ別、エンドユーザー別、地域別、機会、予測(2017年~2031年) |
出版日: 2024年09月03日
発行: Markets & Data
ページ情報: 英文 246 Pages
納期: 3~5営業日
|
世界の心電計(ECG)の市場規模は、2023年の84億190万米ドルから2031年に152億3,169万米ドルに達すると予測され、予測期間の2024年~2031年にCAGRで7.72%の成長が見込まれます。市場は、心疾患の増加によって着実に伸びており、今後も大きな成長が見込まれます。
心電計は、心拍を記録し、心血管障害の可能性を分析するために使用される機器であり技術です。心血管系疾患の負担が増加するにつれて、ECG処置や新しい機器に対する需要も増加しています。ECG機器市場は、設計や機能の技術的進歩、AIや機器学習の統合、ECGの記録に用いるウェアラブル機器の成長動向などの要因の影響下で成長すると予測されます。十分な数の医療機器を整備して医療インフラを強化する政府の取り組みが、市場の成長を後押ししています。さらに、ECG機器に技術を統合する投資の増加や新興スタートアップが市場成長を後押ししています。
例えば2024年4月、ベンガルールのヘルステックスタートアップであるTricog Health India Pvt Ltd.は、OMRON Healthcare India Pvt Ltd.やSony Innovation Fundなどの投資家からSeries B2資金調達ラウンドで850万米ドルを調達しました。同社はAIを使ってECG/EKGやECHOスキャンを分析し、心臓の異常を診断しており、今回の資金調達はAIを活用した心臓ケアソリューションのさらなる発展につながります。しかし、複数の促進要因があるにもかかわらず、多数のローカル企業による市場の飽和や、国によって異なる厳しい規制手続きなどの課題が、市場成長の大きな妨げとなっています。
心血管疾患の有病率の上昇
世界の心血管疾患の負担の増加は、これらの疾患の早期発見と管理を可能にするECG機器と関連診断技術の需要の増加と採用の主な促進要因です。心血管系疾患は主にECG技術で診断されるため、心血管疾患の負担の増加はECG機器とサービスの需要を高めることになります。American Heart Association、British Heart Foundation、WHOなど、心血管の健康に向け活動しているさまざまな団体は、一貫して心血管疾患の大幅な増加を報告しています。例えば2024年6月、American Heart Associationの2つの新しい会長推奨で報告された予測によると、米国人口の61%を超える1億8,400万人以上が何らかの心血管疾患(CVD)に罹患する可能性があり、CVD関連の総費用は2050年までに3倍の1兆8,000億米ドルに達すると予測されています。
技術の進歩が市場成長を促進
その他の医療技術の領域と同様に、ECG機器も複数の技術的進歩を示しています。近年の技術の進歩には、ウェアラブルECG機器(米国FDA承認のApple Watch Series 4など)、AI支援ECG解釈、ポータブルECGモニター、非接触モニタリングシステム、クラウドベースシステム、遠隔医療との統合などがあります。これらの進歩は、心疾患の診断精度を向上させ、データ収集と分析の効率を高めることを目的としています。ECGにおけるAIの統合は劇的な改善をもたらし、患者がECGサービスに容易にアクセスできるようになり、その後の市場拡大につながると予測されます。例えば2024年5月、OMRON Healthcare India Pvt LtdはAliveCor India(AliveCorの子会社)との提携を発表しました。この提携により、オムロンは血圧モニタリング製品に加え、AIベースのハンドヘルドポータブルECG技術を提供することになります。この提携により、心房細動を含むさまざまな不整脈を検出し、心血管疾患の早期発見と管理を提供できる機器が誕生します。この契約は、特に高血圧とECGモニタリングの格差が大きいインドのような国において、心血管の健康に対する意識を高め、発症を予防することを目的としています。
当レポートでは、世界の心電計(ECG)市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。
Global electrocardiograph (ECG) market is projected to witness a CAGR of 7.72% during the forecast period 2024-2031, growing from USD 8401.90 million in 2023 to USD 15231.69 million in 2031. The market for ECG devices is rising consistently due to increasing cardiac diseases and is anticipated to keep growing at a significant rate.
An electrocardiograph is a device and technique used to record the heartbeat and analyze any possible cardiovascular disorder. As the burden of cardiovascular diseases increases, the demand for more ECG procedures and new devices subsequently rises. The market for ECG devices is anticipated to thrive under the influence of factors like technical advancements in design and functions, integration of artificial intelligence (AI) and machine learning, the growing trend of wearable devices for recording ECG, etc. The government initiatives to strengthen the healthcare infrastructure by establishing an adequate number of medical devices drive the growth in the market. Additionally, rising investments and emerging startups integrating technology in ECG devices are boosting the market growth.
For instance, in April 2024, Tricog Health India Pvt Ltd., a Bengaluru-based health tech startup, raised USD 8.5 million in a Series B2 funding round from investors including OMRON Healthcare India Pvt Ltd and Sony Innovation Fund. The company uses AI to analyze ECG/EKG and ECHO scans to diagnose heart anomalies, and the new funding will help it further develop its AI-powered cardiac care solutions. However, despite several driving forces, challenges like saturation in the market due to the large number of local players, and stringent regulatory procedures varying from country to country pose significant hindrances to market growth.
Rising Prevalence of Cardiovascular Diseases
The rising burden of cardiovascular diseases globally is a key factor fueling increased demand and adoption of ECG machines and related diagnostic technologies to enable earlier detection and management of these conditions. Cardiovascular diseases are mainly diagnosed with ECG technology, which implies that an increase in cardiovascular disease burden will enhance the demand for ECG devices and services. Various associations working for cardiovascular health, such as the American Heart Association, the British Heart Foundation, and WHO, are consistently reporting a significant rise in cardiac diseases. For instance, in June 2024, as per the projections reported in two new American Heart Association presidential advisories, more than 184 million people, exceeding 61% of the U.S. population, are likely to have some type of cardiovascular disease (CVD) and total CVD-related costs are expected to triple to USD 1.8 trillion by 2050.
Technological Advancements Drive Market Growth
Aligning with other domains of medical technology, ECG devices are also undergoing several technical advancements. Some of the recent technical advancements include wearable ECG devices (for example, U.S. FDA-approved Apple Watch Series 4), AI-assisted ECG interpretation, portable ECG monitors, contactless monitoring systems, cloud-based systems, integration with telemedicine, and many more. These advances aim to improve accuracy in the diagnosis of heart conditions and enhance the efficiency of data collection and analysis. AI integration in ECG is anticipated to result in drastic improvements, leading to easy patient access to ECG services and subsequent market expansion. For instance, in May 2024, OMRON Healthcare India Pvt Ltd announced a collaboration with AliveCor India (a subsidiary of AliveCor, Inc.). Through this partnership, OMRON will now offer AI-based handheld portable ECG technology in addition to its blood pressure monitoring products. The collaboration will result in devices that can detect various heart arrhythmias, including atrial fibrillation, and provide early cardiovascular disease detection and management. The deal aims to enhance cardiovascular health awareness and prevent incidents, especially in a country like India, where hypertension and ECG monitoring gaps are significant.
Devices Segment Dominates the Global (ECG) Market
ECG device installations are increasing with the expanding healthcare infrastructure. With the rising burden of cardiac diseases and subsequent demand for more ECG procedures and devices, the ECG device segment is anticipated to cover a major market share. Technical advancements and device upgrades in diagnostic centers and hospitals further catalyze the increasing market share of the devices segment. For example, in January 2024, Wellysis Corp. launched its revolutionary electrocardiogram (ECG) monitoring solution, 'S-Patch,' into the lucrative United States and Indian markets. The company has secured a strategic supply agreement with a leading provider of ECG services in the United States, initially deploying 1,000 devices across Texas, Arizona, and Louisiana, with a two-year supply commitment. Additionally, Wellysis has partnered with Turtle Shell Technologies Private Limited (Dozee), a prominent bed monitoring solutions provider in India, to integrate and supply 50,000 S-Patch devices to hospital beds starting in January.
North America Dominates Electrocardiograph (ECG) Market Share
North America is anticipated to dominate the ECG market. North America, particularly the United States, has a significant demand for ECG devices due to several key factors. The high prevalence of cardiovascular diseases, an aging population, and a well-developed healthcare infrastructure with robust reimbursement policies have all contributed to this demand. Sustained efforts by healthcare organizations like the U.S. FDA to raise awareness about heart health and product approvals are also driving the demand for these diagnostic and monitoring tools in North America. For instance, in June 2024, Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device, an AI-based algorithm designed to identify patients at increased risk of atrial fibrillation (AF). This innovative technology uses machine learning to analyze 12-lead electrocardiogram (ECG) recordings, helping clinicians detect signs of AF within the next 12 months. The device is intended for use on resting ECG recordings from patients aged 65 and older without a known history of AF.
Future Market Scenario (2024-2031F)
ECG technology plays a pivotal role in the cardiology domain, and with growing advancements, the machinery for recording ECG has changed drastically in recent years. The evolving trend of wearable devices has greatly impacted ECG monitoring as well. Nowadays, several smartwatches and other kinds of wearable devices are available in the market that can easily record patients' ECGs. This is anticipated to revolutionize the ECG market in upcoming years. Market players are also actively developing wearable devices to cater to the rising demand. For instance, in September 2023, iRhythm Technologies, Inc. launched its next-generation Zio monitor. This prescription-only ECG monitoring device is part of the company's Zio long-term continuous monitoring (LTCM) service. The new Zio monitor is 23% thinner, 62% lighter, and 72% smaller than its predecessor, enhancing patient comfort and adherence. It features a waterproof design and requires no device or adhesive manipulation during the 14-day wear period.
Key Players Landscape and Outlook
GE HealthCare Technologies, Inc., Koninklijke Philips N.V., Hill-Rom Holdings, Inc., NIHON KOHDEN CORPORATION, Fukuda Denshi Co Ltd, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Schiller AG, Spacelabs Healthcare, Inc., BPL MEDICAL TECHNOLOGIES PRIVATE LIMITED, Allengers Medical Systems Ltd are some of the leading players in the ECG market. The market witnessed some substantial market deals like mergers and collaborations to expand the market share of key players.
In February 2024, Thyrocare Technologies Ltd., a leading diagnostic service provider, acquired Chennai-based Think Health Diagnostics Pvt Ltd to expand its presence in the pre-policy medical check-up segment for the insurance market by offering both blood tests and ECGs as a one-stop solution, leveraging Think Health's operational presence in 10 cities and Thyrocare's network of over 900 blood collection phlebotomists trained to provide ECGs at home, aiming to expand these services to more than 100 cities in the next year and deliver seamless healthcare directly to patient's doorsteps.
In May 2024, WearLinq, Inc. acquired AMI Cardiac Monitoring LLC, which is an independent diagnostic testing facility with over 33 years of expertise in ambulatory cardiac monitoring. This strategic acquisition will expand WearLinq's clinical services across all 50 U.S. states and provide more patients access to its FDA-cleared 6-lead wearable ECG monitor, the eWave. The combined capabilities of AMI's clinical expertise and WearLinq's advanced technology are expected to revolutionize the field of ambulatory cardiac monitoring, enabling more accurate diagnoses and improved patient outcomes.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.